Keyphrases
Cost-effectiveness
100%
Conventional Chemotherapy
100%
Interferon-α (IFN-α)
100%
Chronic Myeloid Leukemia
100%
Hydroxyurea
54%
Quality of Life
36%
Lifesaving
36%
Remission
36%
Hematologic
36%
Quality-adjusted
36%
Chronic Phase
27%
Bone Marrow Transplantation
18%
Initial Treatment
18%
Interferon Therapy
18%
Markov Model
18%
Cytogenetic Response
18%
Blast Crisis
18%
Hydroxyurea Therapy
18%
Clinical Trials
9%
Clinical Investigator
9%
Health Status
9%
University Medical Centre
9%
Median Survival
9%
Life Expectancy
9%
North America
9%
Quality Measures
9%
Clinical Scenarios
9%
Natural History
9%
Conventional Therapy
9%
Meta-analysis
9%
Model Prediction
9%
Therapeutic Process
9%
Life Cost
9%
Decision-analytic Model
9%
Accelerated Phase
9%
Marginal Cost
9%
North Europe
9%
Therapy Costs
9%
Quality-adjusted Life Expectancy
9%
Discounted Cost
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Chronic Myeloid Leukemia
100%
Interferon
100%
Hydroxycarbamide
61%
Remission
30%
Life Expectancy
15%
Blast Cell Crisis
15%
Clinical Study
7%
Clinical Trial
7%